Focused On-demand Library for PHD finger protein 6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8IWS0

UPID:

PHF6_HUMAN

Alternative names:

PHD-like zinc finger protein

Alternative UPACC:

Q8IWS0; A8K230; B4E0G4; D3DTG3; E9PC97; Q5JRC7; Q5JRC8; Q96JK3; Q9BRU0

Background:

PHD finger protein 6, also known as PHD-like zinc finger protein, plays a pivotal role in cellular processes by associating with ribosomal RNA promoters to suppress ribosomal RNA transcription. This regulatory function is crucial for maintaining cellular homeostasis and ensuring proper protein synthesis rates.

Therapeutic significance:

Given its involvement in Boerjeson-Forssman-Lehmann syndrome, a disorder marked by intellectual disability and metabolic abnormalities, PHD finger protein 6 presents a promising target for therapeutic intervention. Understanding the role of PHD finger protein 6 could open doors to potential therapeutic strategies aimed at mitigating the symptoms of this syndrome.